Brandenburg Kapital - News about Lindis Blood Care GmbH
Lindis Blood Care announces Publication of Clinical Pilot Study
Henningsdorf/Berlin - Dec. 2021. Lindis Blood Care, a portfolio company of Brandenburg Kapital that aims to revolutionize blood management during cancer surgeries with its medical device CATUVAB® for the removal of tumor cells from surgical shed blood, announced succesful results from their ex-vivo Pilot study with 16 cancer patients in November this year. The study results have shown efficacy and feasibility with no residual malignant cells detetected in the final erythrocyte concentrates after CATUVAV® procedere.
The study in 16 patients undergoing abdominal tumor resection investigated the feasibility, efficacy and safety aspects of the newly developed CATUVAB® procedure.
Please read more information about Lindis Blood Care GmbH below in the download section.
Brandenburg Kapital GmbH has been supporting the company since 2019.
About Lindis Blood Care:
Lindis Blood Care is a medical technology company developing the medical device CATUVAB®. CATUVAB® is used to remove EpCAM-positive tumor cells from surgical blood with the use of MAT (machine autotransfusion) technology, which is generally used today to re-transfuse surgical shed blood in non-oncological procedures. The product and process can be integrated easily into everyday clinical practice and become part of contemporary "patient blood management".
For more information, see www.brandenburg-kapital.de and www.lindis-bloodcare.com